Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
45
BOLT Quote, Financials, Valuation and Earnings
Last price:
$5.31
Seasonality move
:
-11.17%
Day range:
$5.11 - $5.45
52-week range:
$4.41 - $12.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.50x
P/B ratio:
0.32x
Volume:
5.9K
Avg. volume:
31.6K
1-year change:
-51.87%
Market cap:
$10.4M
Revenue:
$7.7M
EPS (TTM):
-$16.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$820.8K | -$5.40 | -28.06% | -33.72% | $22.00 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.1M | -$0.64 | -81.58% | -19.67% | $91.42 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$5.42 | $22.00 | $10.4M | -- | $0.00 | 0% | 11.50x |
|
AVXL
Anavex Life Sciences Corp.
|
$4.40 | $22.00 | $393.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PTGX
Protagonist Therapeutics, Inc.
|
$89.65 | $91.42 | $5.6B | 141.56x | $0.00 | 0% | 27.49x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
42.36% | 0.923 | 231.3% | 3.28x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.178 | 0.26% | 12.83x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$1.9M | -$7.7M | -58.81% | -86.41% | -355.14% | -$9.8M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Bolt Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns BOLT or AVXL?
Anavex Life Sciences Corp. has a net margin of -329.37% compared to Bolt Biotherapeutics, Inc.'s net margin of --. Bolt Biotherapeutics, Inc.'s return on equity of -86.41% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.86.63% -$3.72 $55.7M AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M -
What do Analysts Say About BOLT or AVXL?
Bolt Biotherapeutics, Inc. has a consensus price target of $22.00, signalling upside risk potential of 305.9%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 400%. Given that Anavex Life Sciences Corp. has higher upside potential than Bolt Biotherapeutics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Bolt Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 3 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is BOLT or AVXL More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.
-
Which is a Better Dividend Stock BOLT or AVXL?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or AVXL?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.2M, which are larger than Anavex Life Sciences Corp. quarterly revenues of --. Bolt Biotherapeutics, Inc.'s net income of -$7.1M is higher than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 11.50x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.11.50x -- $2.2M -$7.1M AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M
-
Which has Higher Returns BOLT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -329.37% compared to Bolt Biotherapeutics, Inc.'s net margin of -255.85%. Bolt Biotherapeutics, Inc.'s return on equity of -86.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.86.63% -$3.72 $55.7M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BOLT or NBY?
Bolt Biotherapeutics, Inc. has a consensus price target of $22.00, signalling upside risk potential of 305.9%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 3 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BOLT or NBY More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock BOLT or NBY?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or NBY?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.2M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Bolt Biotherapeutics, Inc.'s net income of -$7.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 11.50x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.11.50x -- $2.2M -$7.1M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns BOLT or PTGX?
Protagonist Therapeutics, Inc. has a net margin of -329.37% compared to Bolt Biotherapeutics, Inc.'s net margin of -834.87%. Bolt Biotherapeutics, Inc.'s return on equity of -86.41% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.86.63% -$3.72 $55.7M PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M -
What do Analysts Say About BOLT or PTGX?
Bolt Biotherapeutics, Inc. has a consensus price target of $22.00, signalling upside risk potential of 305.9%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $91.42 which suggests that it could grow by 1.16%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than Protagonist Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 3 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is BOLT or PTGX More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.
-
Which is a Better Dividend Stock BOLT or PTGX?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or PTGX?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.2M, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Bolt Biotherapeutics, Inc.'s net income of -$7.1M is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 141.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 11.50x versus 27.49x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.11.50x -- $2.2M -$7.1M PTGXProtagonist Therapeutics, Inc.27.49x 141.56x $4.7M -$39.3M
-
Which has Higher Returns BOLT or PTN?
Palatin Technologies has a net margin of -329.37% compared to Bolt Biotherapeutics, Inc.'s net margin of --. Bolt Biotherapeutics, Inc.'s return on equity of -86.41% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.86.63% -$3.72 $55.7M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BOLT or PTN?
Bolt Biotherapeutics, Inc. has a consensus price target of $22.00, signalling upside risk potential of 305.9%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Bolt Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Bolt Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 3 0 PTNPalatin Technologies0 0 0 -
Is BOLT or PTN More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BOLT or PTN?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or PTN?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.2M, which are larger than Palatin Technologies quarterly revenues of --. Bolt Biotherapeutics, Inc.'s net income of -$7.1M is higher than Palatin Technologies's net income of --. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 11.50x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.11.50x -- $2.2M -$7.1M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns BOLT or TOVX?
Theriva Biologics, Inc. has a net margin of -329.37% compared to Bolt Biotherapeutics, Inc.'s net margin of --. Bolt Biotherapeutics, Inc.'s return on equity of -86.41% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.86.63% -$3.72 $55.7M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About BOLT or TOVX?
Bolt Biotherapeutics, Inc. has a consensus price target of $22.00, signalling upside risk potential of 305.9%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Bolt Biotherapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Bolt Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 3 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is BOLT or TOVX More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock BOLT or TOVX?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or TOVX?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.2M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Bolt Biotherapeutics, Inc.'s net income of -$7.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 11.50x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.11.50x -- $2.2M -$7.1M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
